EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	763	560/100.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:51
L2	746	560/106.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:51
L3	238	560/223.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:51
L4	613	562/553.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:52
L5	790	564/155.ccls.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:52
L6	3004	L1 OR L2 OR L3 OR L4 OR L5	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:52
L7	7	L6 AND CASPASE$	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:53
L8	45	L6 AND APOPTOSIS	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:57
L9	790	562/450.CCLS.	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:57

EAST Search History

L10	3727	L6 OR L9	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:57
L11	89	L10 AND APOPTOSIS	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:57
L12	20	L10 AND CASPASE$	US-PGPUB; USPAT; FPRS; EPO; JPO; DERWENT	OR	ON	2007/08/07 17:57

STN Structure Search (Registry / Caplus)

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 X,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:59:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:59:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED 50 TO ITERATE

100.0% PROCESSED 50 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

L3 19 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 15:59:19 ON 07 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 6 Aug 2007 (20070806/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:675705 CAPLUS
DOCUMENT NUMBER: 141:207524
TITLE: Preparation of peptidyl irreversible caspase-3 inhibitors as active site probes
INVENTOR(S): Colucci, John; Giroux, Andre; Han, Yongxin; Methot, Nathalie; Nicholson, Donald W.; Roy, Sophie; Vaillancourt, John Paul; Tawa, Paul
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Instant App

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069773	A1	20040819	WO 2004-CA152	20040205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2514441	A1	20041019	CA 2004-2514441	20040205
EP 1594819	A1	20051116	EP 2004-708291	20040205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006519777	T	20060831	JP 2006-501408	20040205
US 2006069038	A1	20060330	US 2005-542684	20050719
PRIORITY APPLN. INFO.:			US 2003-445560P P	20030207
			WO 2004-CA152 W	20040205

OTHER SOURCE(S): MARPAT 141:207524
GI

2/7/03



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

I

II

AB The invention encompasses compds. I [X is halo or O-W-Z, where W is a bond, CH2, CO or COCH2 and Z is H, alkyl, cycloalkyl, Ph, etc.; R2 is H, halo, hydroxy, nitro, cyano, alkyl, etc.; R3 is Ph or (un)substituted alkyl; R4 is H, halo, hydroxy, (un)substituted alkyl or alkoxy; R5 is H, Ph, naphthyl, (un)substituted alkyl or cycloalkyl and R6 is H or R5 and R6 together form a ring] which are useful for determining whether a caspase has been activated in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can be used to calculate the percentage of occupancy of active caspases by other, unlabeled inhibitors. Thus, peptide II was prepared via coupling reactions of Me (5-iodo-2-methoxyphenyl)acetate, L-valine tert-Bu ester hydrochloride, and tert-Bu 3-amino-2,3,5-trideoxy-5-fluoropentonate, followed by tributylstannylation, iodination, and deprotection with TFA. II was assayed for inhibition of a subset of caspases and for detection of active caspases in protein exts.

IT 741292-98-8P 741292-99-9P 741293-00-5P
741293-01-6P 741293-02-7P 741293-03-8P
741293-04-9P 741293-05-0P 741293-06-1P
741293-07-2P 741293-08-3P 741293-09-4P
741293-10-7P 741293-11-8P 741293-12-9P
741293-13-0P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyl irreversible caspase-3 inhibitors as active site probes)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 741292-98-8 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741292-99-9 CAPLUS
CN Pentanoic acid, 5-(acetyloxy)-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-00-5 CAPLUS
CN Pentanoic acid, 5-(benzoyloxy)-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-01-6 CAPLUS
CN Benzoic acid, 2,6-dimethyl-, 4-carboxy-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 741293-02-7 CAPLUS
CN 1-Naphthalenecarboxylic acid, 4-carboxy-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-03-8 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-[[[2-ethoxy-5-(iodo-125I)phenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-5-fluoro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-04-9 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NAME)

Absolute stereochemistry.



RN 741293-05-0 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-1-oxopropyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-06-1 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]phenylacetyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-07-2 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S,3S)-2-[[[5-(iodo-125I)-2-

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methoxyphenyl]acetyl]amino]-3-methyl-1-oxopentyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-08-3 CAPLUS
CN Pentanoic acid, 3-[[(2S)-cyclopentyl[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]acetyl]amino]-5-fluoro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-09-4 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-(1-methylethoxy)phenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 741293-10-7 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-phenoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-11-8 CAPLUS
CN Pentanoic acid, 5-chloro-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 741293-12-9 CAPLUS
CN Pentanoic acid, 5-bromo-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 741293-13-0 CAPLUS
CN Pentanoic acid, 3-[[(2S)-cyclohexyl[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]acetyl]amino]-5-fluoro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 741293-20-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidyl irreversible caspase-3 inhibitors as active site probes)
RN 741293-20-9 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[(5-iodo-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:524634 CAPLUS
DOCUMENT NUMBER: 141:238703
TITLE: A Caspase Active Site Probe Reveals High Fractional Inhibition Needed to Block DNA Fragmentation
AUTHOR(S): Methot, Nathalie; Vaillancourt, John P.; Huang, JingQi; Colucci, John; Han, Yongxin; Menard, Stephane; Zamboni, Robert; Toulmond, Sylvie; Nicholson, Donald W.; Roy, Sophie
CORPORATE SOURCE: Merck Frosst Centre for Therapeutic Research, Merck Research Laboratories, Montreal, QC, H9H 3L1, Can.
SOURCE: Journal of Biological Chemistry (2004), 279(27), 27905-27914
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Apoptotic markers consist of either caspase substrate cleavage products or phenotypic changes that manifest themselves as a consequence of caspase-mediated substrate cleavage. We have shown recently that pharmacol. inhibitors of caspase activity prevent the appearance of two such apoptotic manifestations, αII-spectrin cleavage and DNA fragmentation, but that blockade of the latter required a significantly higher concentration of inhibitor. We investigated this phenomenon through the use of a novel radiolabeled caspase inhibitor, [125I]M808, which acts as a caspase active site probe. [125I]M808 bound to active caspases irreversibly and with high sensitivity in apoptotic cell exts., in tissue exts. from several commonly used animal models of cellular injury, and in living cells. Moreover, [125I]M808 detected active caspases in septic mice when injected i.v. Using this caspase probe, an active site occupancy assay was developed and used to measure the fractional inhibition required to block apoptosis-induced DNA fragmentation. In thymocytes, occupancy of up to 40% of caspase active sites had no effect on DNA fragmentation, whereas inhibition of half of the DNA cleaving activity required between 65 and 75% of active site occupancy. These results suggest that a high and persistent fractional inhibition will be required for successful caspase inhibition-based therapies.
IT 741292-98-8P, [125I]M 808
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
(active site probe [125I]M808 reveals high fractional inhibition of human caspase-3 is needed to block apoptosis-induced DNA fragmentation)
RN 741292-98-8 CAPLUS
CN Pentanoic acid, 5-fluoro-3-[[(2S)-2-[[[5-(iodo-125I)-2-methoxyphenyl]acetyl]amino]-3-methyl-1-oxobutyl]amino]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:185062 CAPLUS
DOCUMENT NUMBER: 136:232548
TITLE: Preparation of γ-keto acid dipeptides as inhibitors of caspase-3
INVENTOR(S): Han, Yongxin; Giroux, Andre; Grimm, Erich L.; Aspiotis, Renee; Black, Cameron
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020465	A2	20020314	WO 2001-CA1272	20010906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421172	A1	20020314	CA 2001-2421172	20010906
AU 2001093533	A5	20020322	AU 2001-93533	20010906
EP 1317414	A2	20030611	EP 2001-973867	20010906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525080	T	20040715	JP 2002-525088	20010906
US 2002165230	A1	20021107	US 2001-948244	20010907
US 6525025	B2	20030225		
PRIORITY APPLN. INFO.:			US 2000-231019P P	20000908
			WO 2001-CA1272 W	20010906

OTHER SOURCE(S): MARPAT 136:232548
AB γ-Keto acid dipeptides RCR1CONHCR2R3CONHCH(CH2CO2H)COCH2-O-W-Z [W = a bond, CH2, CO or COCH2; Z = H, (un)substituted alkyl, cycloalkyl or a benzofused analog, Ph, naphthyl or a 5- to 10-membered mono- or bicyclic, aromatic or non-aromatic ring, or a benzofused analog, containing 1-3 heteroatoms selected from O, S and N; R = (un)substituted alkoxyphenyl; R1 = H, halo, OH, alkyl or alkoxy optionally substituted by oxo or 1-3 halo groups; R2 = H, Ph, naphthyl, (un)substituted (cyclo)alkyl; R3 = H or R2R3 represent a 4-7 membered ring optionally containing one heteroatom selected from O, S and N] were prepared as inhibitors of caspase-3. Thus, (3S)-5-[(2-chloro-6-fluorobenzyl)oxy]-3-[[(2S)-2-[[2-(2,5-dimethoxyphenyl)acetyl]amino]-3-methylbutanoyl]amino]-4-oxopentanoic acid was prepared by the solid phase method by loading (S)-FmocNHCH(CH2CO2Bu-t)COCH2Br (Fmoc = fluorenylmethoxycarbonyl) (preparation described) onto a solid support using the technol. described by Webb et al. (1992).
IT 403499-45-6P 403499-46-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of γ-keto acid dipeptides as inhibitors of caspase-3)
RN 403499-45-6 CAPLUS
CN 1-Naphthalenecarboxylic acid, 4-carboxy-3-[[(2S)-2-[[hydroxy(5-iodo-2-methoxyphenyl)acetyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403499-46-7 CAPLUS
CN Pentanoic acid, 3-[[(2S)-2-[[hydroxy(5-iodo-2-methoxyphenyl)acetyl]amino]-3-methyl-1-oxobutyl]amino]-5-(1-naphthalenyloxy)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.